Helix BioPharma Corp.
HBP.TOTSXHealthcare● Active
$1.53
$-0.05(-3.16%)
Market Cap$116858490
P/E Ratio—
52W High$5.4
52W Low$0.84
Helix BioPharma Corp.（HBP.TO）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · HBP.TO · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-07 | 2024-07 | 2023-07 | 2022-07 | 2021-07 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Receivables | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| PP&E Net | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.02B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $0.02B | $0.00B | $0.00B | $0.00B | $0.00B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Liabilities | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Long-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Liabilities | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.22B) | ($0.21B) | ($0.20B) | ($0.20B) | ($0.19B) |
| Total Stockholders Equity | $0.02B | ($0.00B) | ($0.00B) | $0.00B | ($0.00B) |
| Total Liab & Equity(computed) | $0.02B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Summary | |||||
| Total Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Debt | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · CAD · B
深入了解Helix BioPharma Corp.
关于Helix BioPharma Corp.（HBP.TO）资产负债表
Helix BioPharma Corp.总资产$0.02B，现金及短期投资$0.00B，总负债$0.00B，总债务$0.00B，股东权益$0.02B。
常见问题
HBP.TO · 4 问Helix BioPharma Corp.总债务$0.00B，净债务$0.00B。
HBP.TO total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10